1.

Genetic characterization of ESBL-producing and ciprofloxacin-resistant Escherichia coli from Belgian broilers and pigs

2.

Genetic characterization of ESBL-producing and ciprofloxacin-resistant Escherichia coli from Belgian broilers and pigs

3.

Genetic characterization of ESBL-producing and ciprofloxacin-resistant Escherichia coli from Belgian broilers and pigs

4.

Genetic characterization of ESBL-producing and ciprofloxacin-resistant Escherichia coli from Belgian broilers and pigs

5.

Genetic characterization of ESBL-producing and ciprofloxacin-resistant Escherichia coli from Belgian broilers and pigs

6.

Genetic characterization of ESBL-producing and ciprofloxacin-resistant Escherichia coli from Belgian broilers and pigs

7.

Genetic characterization of ESBL-producing and ciprofloxacin-resistant Escherichia coli from Belgian broilers and pigs

8.

Genetic characterization of ESBL-producing and ciprofloxacin-resistant Escherichia coli from Belgian broilers and pigs

1.

Haemophilus influenzae carriage and antibiotic resistance profile in Belgian infants over a three-year period (2016–2018)

2.

Haemophilus influenzae carriage and antibiotic resistance profile in Belgian infants over a three-year period (2016–2018)

3.

Haemophilus influenzae carriage and antibiotic resistance profile in Belgian infants over a three-year period (2016–2018)

4.

Haemophilus influenzae carriage and antibiotic resistance profile in Belgian infants over a three-year period (2016–2018)

5.

Haemophilus influenzae carriage and antibiotic resistance profile in Belgian infants over a three-year period (2016–2018)

6.

Haemophilus influenzae carriage and antibiotic resistance profile in Belgian infants over a three-year period (2016–2018)

7.

Haemophilus influenzae carriage and antibiotic resistance profile in Belgian infants over a three-year period (2016–2018)

1.

Retrospective surveillance of viable Bacillus cereus group contaminations in commercial food and feed vitamin B2 products sold on the Belgian market using whole-genome sequencing

2.

Retrospective surveillance of viable Bacillus cereus group contaminations in commercial food and feed vitamin B2 products sold on the Belgian market using whole-genome sequencing

3.

Retrospective surveillance of viable Bacillus cereus group contaminations in commercial food and feed vitamin B2 products sold on the Belgian market using whole-genome sequencing

4.

Retrospective surveillance of viable Bacillus cereus group contaminations in commercial food and feed vitamin B2 products sold on the Belgian market using whole-genome sequencing

5.

Retrospective surveillance of viable Bacillus cereus group contaminations in commercial food and feed vitamin B2 products sold on the Belgian market using whole-genome sequencing

6.

Retrospective surveillance of viable Bacillus cereus group contaminations in commercial food and feed vitamin B2 products sold on the Belgian market using whole-genome sequencing

7.

Retrospective surveillance of viable Bacillus cereus group contaminations in commercial food and feed vitamin B2 products sold on the Belgian market using whole-genome sequencing

8.

Retrospective surveillance of viable Bacillus cereus group contaminations in commercial food and feed vitamin B2 products sold on the Belgian market using whole-genome sequencing

1.

Analyses of the bacterial contamination on Belgian broiler carcasses at retail level

2.

Analyses of the bacterial contamination on Belgian broiler carcasses at retail level

1.

Fig 6 -

2.

Fig 6 -

3.

Fig 6 -

4.

Fig 6 -

5.

Fig 6 -

6.

Fig 6 -

7.

Fig 6 -

8.

Fig 6 -

9.

Fig 6 -

1.

Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults

2.

Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults

1.

Additional file 1 of Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series

2.

Additional file 1 of Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series

3.

Additional file 1 of Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series

4.

Additional file 1 of Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series

5.

Additional file 1 of Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series

6.

Additional file 1 of Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series

1.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

2.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

3.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

4.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

5.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

6.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

7.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

8.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

9.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

1.

S2 Fig -

2.

S2 Fig -

3.

S2 Fig -

4.

S2 Fig -

5.

S2 Fig -

6.

S2 Fig -

7.

S2 Fig -

8.

S2 Fig -

9.

S2 Fig -

1.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

2.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

3.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

4.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

5.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

6.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

7.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

8.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

9.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.